<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="TB1" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <title>Coalition for Epidemic Preparedness Innovations Vaccine-Development Partnerships up to March 2019</title>
 </caption>
 <table frame="hsides" rules="groups">
  <colgroup span="1">
   <col align="left" span="1"/>
   <col align="left" span="1"/>
   <col align="left" span="1"/>
  </colgroup>
  <thead>
   <tr valign="top">
    <th align="center" rowspan="1" colspan="1">
     <bold>Company</bold>
    </th>
    <th align="center" rowspan="1" colspan="1">
     <bold>Development</bold>
     <sup>a</sup>
    </th>
    <th align="center" rowspan="1" colspan="1">
     <bold>Date of Partnership Announcement</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Themis Bioscience</td>
    <td align="left" rowspan="1" colspan="1">$37.5 million to develop a vaccine against Lassa virus and MERS-CoV, using a measles vector technology</td>
    <td align="left" rowspan="1" colspan="1">March 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Inovio</td>
    <td align="left" rowspan="1" colspan="1">$56 million to develop a DNA vaccine against Lassa virus and MERS-CoV</td>
    <td align="left" rowspan="1" colspan="1">April 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">IAVI</td>
    <td align="left" rowspan="1" colspan="1">$54.9 million to develop a vaccine against Lassa virus, using a replication-competent vesicular stomatitis virus vector technology</td>
    <td align="left" rowspan="1" colspan="1">May 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Profectus Biosciences, Emergent, and PATH</td>
    <td align="left" rowspan="1" colspan="1">$25 million to develop a recombinant subunit protein vaccine against Nipah virus</td>
    <td align="left" rowspan="1" colspan="1">May 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Profectus Biosciences, Emergent, and PATH</td>
    <td align="left" rowspan="1" colspan="1">$36 million to develop an attenuated VesiculoVax vaccine against Lassa virus</td>
    <td align="left" rowspan="1" colspan="1">June 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">IDT Biologika</td>
    <td align="left" rowspan="1" colspan="1">$36 million to develop a vaccine against MERS-CoV virus, using a recombinant, modified vaccinia Ankara vector technology</td>
    <td align="left" rowspan="1" colspan="1">August 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Janssen and University of Oxford</td>
    <td align="left" rowspan="1" colspan="1">$19 million to develop a vaccine against Lassa virus, MERS-CoV, and Nipah virus, using a simian adenoviral vaccine vector technolog</td>
    <td align="left" rowspan="1" colspan="1">September 2018</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Imperial College</td>
    <td align="left" rowspan="1" colspan="1">$8.4 million to develop a self-amplifying RNA vaccine platform that enables tailored vaccine production against multiple viral pathogens (including H1N1 influenza, rabies virus, and Marburg virus)</td>
    <td align="left" rowspan="1" colspan="1">December 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">University of Queensland</td>
    <td align="left" rowspan="1" colspan="1">$10.6 million to develop a “molecular clamp” vaccine platform, a transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens (including influenza virus, MERS-CoV, and respiratory syncytial virus)</td>
    <td align="left" rowspan="1" colspan="1">December 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">University of Tokyo</td>
    <td align="left" rowspan="1" colspan="1">$31 million to develop a vaccine against Nipah virus by inserting the Nipah-virus G gene (Malaysia strain) into a measles vector (Edmonston B strain)</td>
    <td align="left" rowspan="1" colspan="1">February 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">CureVac</td>
    <td align="left" rowspan="1" colspan="1">$34 million to develop The RNA Printer prototype, a transportable, down-scaled, automated mRNA printing facility, that can produce rapidly a supply of lipid-nanoparticle–formulated mRNA vaccine candidate that can target known pathogens (including Lassa fever, yellow fever, and rabies); and prepare for rapid response to unknown pathogens (i.e., Disease X)</td>
    <td align="left" rowspan="1" colspan="1">February 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Themis Bioscience</td>
    <td align="left" rowspan="1" colspan="1">$21 million to advance a vaccine against chikungunya virus through phase 3 clinical trials and to accelerate its regulatory approval so at-risk populations have access to the vaccine, using a measles vector technology</td>
    <td align="left" rowspan="1" colspan="1">June 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Wageningen Bioveterinary Research</td>
    <td align="left" rowspan="1" colspan="1">$12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate against Rift Valley fever, using an attenuated virus technology</td>
    <td align="left" rowspan="1" colspan="1">July 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Colorado State University</td>
    <td align="left" rowspan="1" colspan="1">$9.5 million for manufacturing and preclinical studies to assess a single-dose vaccine candidate against Rift Valley fever, using an attenuated virus technology</td>
    <td align="left" rowspan="1" colspan="1">July 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Valneva</td>
    <td align="left" rowspan="1" colspan="1">$23.4 million for vaccine manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine against chikungunya virus</td>
    <td align="left" rowspan="1" colspan="1">July 2019</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Public Health Vaccines</td>
    <td align="left" rowspan="1" colspan="1">$43.6 million to advance the development and manufacture of a vaccine against the Nipah virus, using a recombinant vesicular stomatitis virus technology</td>
    <td align="left" rowspan="1" colspan="1">August 2019</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; mRNA, messenger RNA.</p>
  <p>
   <sup>a</sup> Cited funding is reported in US dollars.
  </p>
 </table-wrap-foot>
</table-wrap>
